Evidence map›Paper›PMID 30655593›Full record

ArticleScientific reports2019

Identification of selective inhibitors of Helicobacter pylori IMPDH as a targeted therapy for the infection.

Kapil Juvale, Gayathri Purushothaman, Vijay Singh, Althaf Shaik, Srimadhavi Ravi, Vijay Thiruvenkatam, Sivapriya Kirubakaran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Anti-Heliyon · 2024
    Article
  3. Anti-Foods (Basel, Switzerland) · 2021
    Article
  4. Evaluation of Bronopol and Disulfiram as PotentialMolecules (Basel, Switzerland) · 2020
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kapil JuvaleChemistry, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, 382355, India.
Gayathri PurushothamanBiological engineering, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, 382355, India.
Vijay SinghBiological engineering, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, 382355, India.
Althaf ShaikChemistry, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, 382355, India.
Srimadhavi RaviChemistry, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, 382355, India.
Vijay ThiruvenkatamBiological engineering, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, 382355, India.
Sivapriya KirubakaranChemistry, Indian Institute of Technology Gandhinagar, Palaj, Gandhinagar, 382355, India. priyak@iitgn.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter pylori (H. pylori), the major cause of several gastric disorders has been recognied as a type I carcinogen. By virtue of resistance developed by H. pylori strains, currently used antibiotic based treatments rather demonstrate high failure rates. Hence, there is an emerging need for identification of new targets to treat H. pylori infection. Inosine-5'-monophosphate dehydrogenase (IMPDH) has been studied as a potential target to treat H. pylori infection. Here, a detailed enzyme kinetic study of recombinant expressed H. pylori inosine-5'-monophosphate dehydrogenase (HpIMPDH) is presented. A new in-house synthesized indole-based scaffold is identified as an inhibitor for HpIMPDH. These indole-based compounds showed non-competitive inhibition against IMP and NAD

Indexed as

Anti-Bacterial AgentsBacterial ProteinsEnzyme InhibitorsHelicobacter InfectionsHelicobacter pyloriHumansIMP DehydrogenaseIndolesKineticsMolecular Targeted TherapyRecombinant ProteinsAnti-Bacterial AgentsBacterial ProteinsEnzyme InhibitorsIMP DehydrogenaseindoleIndolesRecombinant Proteins

Identifiers

PMID30655593
PMCPMC6336804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.